{"nct_id":"NCT02156804","title":"A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)","status":"COMPLETED","status_verified_date":"2020-09","start_date":"2014-10-07","start_date_type":"ACTUAL","primary_completion_date":"2019-01-18","primary_completion_date_type":"ACTUAL","completion_date":"2019-01-18","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["BMY"]}